Wang Y, Zhao X, Gao D, et al. - A randomized clinical trial was designed to analyze the efficacy and safety of leflunomide (LEF) and glucocorticoids (GCs) combination therapy compared with GCs monotherapy in preventing relapse of IgG4-related disease (IgG4-RD). A total of 66 individuals with active IgG4-RD were enrolled (33 patients in each group). Individuals with active IgG4-RD were assigned randomly to the GCs + LEF (20 mg/day) combination therapy or GCs monotherapy group. The time to relapse was considered a primary outcome and complete response, remission, GCs dosage, and serum IgG4 level were secondary outcomes. For the prevention of the relapse of IgG4-RD, LEF in combination with GCs therapy is well-tolerated and significantly superior to GCs monotherapy. However, in the management of IgG4-RD, LEF can be applied as a steroid-sparing agent.